3-((4-((2,2-difluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)amino)-5-methylpyrimidin-2-yl)amino)benzenesulfonamide

ID: ALA5208935

PubChem CID: 67046929

Max Phase: Preclinical

Molecular Formula: C19H16F2N6O4S

Molecular Weight: 462.44

Names and Identifiers

Canonical SMILES:  Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc2c(c1)NC(=O)C(F)(F)O2

Standard InChI:  InChI=1S/C19H16F2N6O4S/c1-10-9-23-18(25-11-3-2-4-13(7-11)32(22,29)30)27-16(10)24-12-5-6-15-14(8-12)26-17(28)19(20,21)31-15/h2-9H,1H3,(H,26,28)(H2,22,29,30)(H2,23,24,25,27)

Standard InChI Key:  HVLJIZBQOBSBKA-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
   -5.4146    0.6154    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5896    0.6154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0028    1.3313    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5896   -0.2097    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3041   -0.6222    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8749   -0.6224    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1602   -0.2097    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4424   -0.6239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7307   -0.2072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0161   -0.6197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3015   -0.2072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4158   -0.6214    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1274   -0.2051    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8420   -0.6176    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5564   -0.2051    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2740   -0.6193    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9856   -0.2030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7002   -0.6154    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    5.1118   -1.3313    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.2868   -1.3313    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.4146   -0.2030    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9856    0.6179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2693    1.0305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5564    0.6199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1274    0.6158    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4112    1.0284    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3015    0.6178    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0159    1.0303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7307    0.6138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4474    1.0264    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1602    0.6154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8749    1.0281    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  4  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 18 20  2  0
 18 21  1  0
 17 22  1  0
 22 23  2  0
 23 24  1  0
 24 15  2  0
 13 25  1  0
 25 26  2  0
 26 27  1  0
 27 11  2  0
 27 28  1  0
  9 29  1  0
 29 30  2  0
 31 30  1  0
  7 31  2  0
 31 32  1  0
  2 32  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5208935

   3-[[4-[(2,2-difluoro-3-oxo-4H-1,4-benzoxazin-6-yl)amino]-5-methylpyrimidin-2-yl]amino]benzenesulfonamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 462.44

Molecular Weight (Monoisotopic): 462.0922

AlogP: 2.84

#Rotatable Bonds: 5

Polar Surface Area: 148.33

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 10

HBD (Lipinski): 5

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.76

CX Basic pKa: 4.25

CX LogP: 3.26

CX LogD: 3.25

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.45

Np Likeness Score: -1.34

References

1. Chen Y, Li H, Yen R, Heckrodt TJ, McMurtrie D, Singh R, Taylor V, Masuda ES, Park G, Payan DG..  (2022)  Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate.,  13  (11.0): [PMID:36385926] [10.1021/acsmedchemlett.2c00411]

Source

Source(1):

• Scientific Literature